IL6R and rheumatoid arthritis: Initially used for treatment of RA, the anti-IL-6R antibody Tocilizumab has since been successfully approved for therapy of systemic juvenile idiopathic arthritis and polyarticular juvenile idiopathic arthritis (Sheppard et al. 2017).